Yuhan Wei1, Qi Du1, Xiaoyue Jiang1, Li Li1, Teng Li1, Mengqi Li1, Xueke Fan2, Yingrui Li3, Seyed Kariminia4, Qin Li5. 1. Department of Oncology, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, 100050, China. 2. Gastroenterology Department, Jincheng People's Hospital, Jincheng, 048000, China. 3. Biochemistry and Molecular Biology, Basic Medicine College, Shanxi Medical University, Taiyuan, 050001, China. 4. Molecular and Cellular Oncology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA. 5. Department of Oncology, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, 100050, China. Electronic address: oncologistinbj@163.com.
Abstract
BACKGROUND: Combination immunotherapy has become an actively growing field of clinical investigation. METHODS: We searched for clinical trials of combination immunotherapy and calculated the pooled hazard ratio (HR), odds ratio (OR) of clinical outcomes and safety by subgroups of different combination regimens. RESULTS: Totally 28 clinical trials were analyzed. The study showed that the pooled HRs of overall survival and progression-free survival for combination therapy were 0.77 (95% CI: 0.70-0.84, p < 0.001) and 0.72 (95% CI: 0.66-0.79, p < 0.001) while the pooled OR of high-grade adverse effects was 1.45 (p = 0.004). Subgroup analysis showed that the HR of overal survival were 0.74 (p = 0.005), 0.79 (p < 0.001), 0.70 (p = 0.003) and 0.85 (p = 0.052) for immunotherapy combined with immunotherapy, chemotherapy, targeted therapy and radiotherapy group, respectively. CONCLUSIONS: The meta-analysis indicated that combination immunotherapy could bring more clinical benefits with increased high-grade adverse effects.
BACKGROUND: Combination immunotherapy has become an actively growing field of clinical investigation. METHODS: We searched for clinical trials of combination immunotherapy and calculated the pooled hazard ratio (HR), odds ratio (OR) of clinical outcomes and safety by subgroups of different combination regimens. RESULTS: Totally 28 clinical trials were analyzed. The study showed that the pooled HRs of overall survival and progression-free survival for combination therapy were 0.77 (95% CI: 0.70-0.84, p < 0.001) and 0.72 (95% CI: 0.66-0.79, p < 0.001) while the pooled OR of high-grade adverse effects was 1.45 (p = 0.004). Subgroup analysis showed that the HR of overal survival were 0.74 (p = 0.005), 0.79 (p < 0.001), 0.70 (p = 0.003) and 0.85 (p = 0.052) for immunotherapy combined with immunotherapy, chemotherapy, targeted therapy and radiotherapy group, respectively. CONCLUSIONS: The meta-analysis indicated that combination immunotherapy could bring more clinical benefits with increased high-grade adverse effects.
Authors: Jeongshim Lee; Jee Suk Chang; Mi Ryung Roh; Minkyu Jung; Choong-Kun Lee; Byung Ho Oh; Kee Yang Chung; Woong Sub Koom; Sang Joon Shin Journal: Cancer Res Treat Date: 2020-02-13 Impact factor: 4.679
Authors: Pier Vitale Nuzzo; Gregory R Pond; Sarah Abou Alaiwi; Amin H Nassar; Ronan Flippot; Catherine Curran; Kerry L Kilbridge; Xiao X Wei; Bradley A McGregor; Toni Choueiri; Lauren C Harshman; Guru Sonpavde Journal: J Immunother Cancer Date: 2020-03 Impact factor: 13.751